康惠股份(603139) - 2018 Q3 - 季度财报

Financial Performance - Operating income for the first nine months was CNY 248,161,889.82, an increase of 6.74% year-on-year[5]. - Net profit attributable to shareholders for the first nine months was CNY 32,837,570.40, a decrease of 9.66% compared to the same period last year[5]. - Basic earnings per share for the reporting period were CNY 0.33, down 19.51% from CNY 0.41 in the previous year[5]. - The company reported a decrease in net profit after deducting non-recurring gains and losses, which was CNY 26,060,433.50, down 28.71% year-on-year[5]. - Total profit for the first nine months was 40,954,359.24, a decrease of 4.6% from 42,941,115.72 in the same period last year[36]. - The total profit for the period was 8,766,542.41 CNY, a decrease from 15,821,996.48 CNY in the previous year, representing a decline of approximately 44.5%[43]. - The net profit for the first nine months was 30,677,769.62 CNY, compared to 36,348,949.43 CNY in the same period last year, indicating a decrease of about 15.6%[43]. Cash Flow - The net cash flow from operating activities for the first nine months was negative CNY 68,214,462.98, a decline of 281.28% year-on-year[5]. - Cash inflow from operating activities totaled 274,840,221.78 CNY, an increase from 250,528,976.36 CNY year-over-year, reflecting a growth of approximately 9.7%[45]. - Cash outflow from operating activities was 343,054,684.76 CNY, up from 268,420,102.68 CNY, resulting in a net cash flow from operating activities of -68,214,462.98 CNY, worsening from -17,891,126.32 CNY last year[47]. - The company reported cash inflow from investment activities of 688,828,481.50 CNY, with a net cash flow from investment activities of -90,063,940.39 CNY, compared to -252,088,075.12 CNY in the previous year[47]. - The cash flow from financing activities resulted in a net outflow of -21,351,905.08 CNY, a significant decrease from a net inflow of 289,975,988.25 CNY last year[49]. - The ending cash and cash equivalents balance was 53,282,579.03 CNY, down from 181,555,624.65 CNY at the end of the previous year[49]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,002,435,640.28, a decrease of 2.85% compared to the end of the previous year[5]. - Current assets totaled CNY 833,856,754.59, down from CNY 877,089,463.03, representing a decrease of about 4.9%[20]. - Total liabilities decreased from CNY 119,697,158.41 to CNY 72,424,186.89, a reduction of about 39.5%[24]. - Current liabilities decreased significantly from CNY 103,441,250.01 to CNY 58,186,746.23, a decline of approximately 43.7%[22]. - Non-current assets increased from CNY 154,718,073.33 to CNY 168,578,885.69, an increase of about 8.9%[20]. - The company's cash and cash equivalents decreased from CNY 230,545,755.89 to CNY 52,163,836.28, a decline of approximately 77.3%[27]. - Accounts receivable decreased from CNY 287,831,057.25 to CNY 273,942,881.80, a decrease of about 4.8%[27]. - The company's retained earnings increased from CNY 359,058,412.84 to CNY 371,919,983.24, an increase of approximately 3.4%[24]. - Total equity increased from CNY 912,110,377.95 to CNY 930,011,453.39, an increase of about 2.0%[24]. Shareholder Information - The total number of shareholders at the end of the reporting period was 11,849[9]. - The largest shareholder, Shaanxi Kanghui Holdings Co., Ltd., held 39,600,000 shares, representing 39.65% of the total shares[9]. Investment Activities - The company completed the acquisition of a 51% stake in Shaanxi Xinhigh Pharmaceutical Co., Ltd., with the registration process finalized[15]. - The company has made significant investments in new partnerships and acquisitions to expand its market presence[15]. - The company received 680,000,000.00 CNY from investment recoveries, which was not reported in the previous year[47]. Expenses - Financial expenses increased by 139.50% to RMB -584,719.75 from RMB -244,146.43, mainly due to increased interest on deposits[12]. - Research and development expenses for Q3 were 1,443,675.16, slightly down from 1,545,965.83 year-over-year[34]. - Sales expenses for Q3 increased to 24,736,924.53, up 9.9% from 21,599,513.29 in the same period last year[34]. - Tax expenses for Q3 were 2,035,105.13, down from 2,832,496.72 in the same period last year[36].